We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Health Service (NHS) and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Eloctaq (efmoroctocog alfa), by lifting prior volume restrictions for the drug.